BioSpace News Archive

Salarius Pharmaceuticals, Inc. announces that it participated in a Type B End-of-Phase 2 meeting with the U.S. Food and Drug Administration to receive guidance regarding the development program for seclidemstat to treat Ewing sarcoma.

Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the third quarter ended September 30, 2023 and provided business highlights.

The Menarini Group and SciClone Pharmaceuticals Ltd. announced that they have entered into an exclusive sub-licensing agreement to develop and commercialize ORSERDU® in the People’s Republic of China, in an effort to expand treatment options for appropriate metastatic breast cancer patients.

Scopus BioPharma Inc. and its majority-owned subsidiary, Duet BioTherapeutics Inc., presented compelling new data that DUET-102 in combination with PD-1 blockade demonstrates significant anti-tumor activity in models of malignant glioma.

Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 2023 Jefferies London Healthcare Conference. Gerald Herman, Executive Vice President & Chief Financial Officer will present and participate in an analyst moderated question and answer session on behalf of the Company on Tuesday, November 14, 2022 at 8:30 AM GMT (3:30 AM Eastern Time).

Gilead Sciences / In the late 1980s, people in Dr. Shyam Sundar’s homeland in eastern India were dying by the hundreds of thousands of a debilitating parasitic disease known as visceral leishmaniasis.

Physicians who care for pregnant women have long sought to identify which of their patients would most likely benefit from monitoring of their fetus’s heart rate to catch early signs of their unborn child developing heart problems tied to the mother’s immune system.

Takeda announced that the company will present positive results from its randomized, double-blind, placebo-controlled, Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 inhibitor with next generation selectivity, in patients with active psoriatic arthritis.

MedStar Washington Hospital Center is one of a select few institutions nationwide now offering patients with abnormally slow heart rates breakthrough technology that delivers treatment by a revolutionary new technology: two tiny leadless pacemakers implanted within the heart.

Calliditas Therapeutics AB announced that management will present at and participate in the following conferences.